SLC5A2 and diabetic kidney disease: Emerging medications such as SGLT2 inhibitors, GLP1 receptor agonists (GLP-1RAs), non-steroidal mineralocorticoid receptor antagonists (nsMRAs) and renin-angiotensin system(RAS) inhibitors, which are known as the four pillars, offer additional treatment options for DKD (124, 125).